ORGANIZATION

• Regenerative Medicine Group Hails Expert Panel’s Proposal on New Pricing Method for Innovative Therapies
  June 9, 2023

• JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
  June 8, 2023

• Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
  June 7, 2023

• Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
  June 7, 2023

• Protect Info for Off-Patent Brands Even after Market Exit: JEMA
  May 29, 2023

• Eisai’s Yasushi Okada Becomes FPMAJ Chairman
  May 26, 2023

• New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
  May 26, 2023

• 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
  May 26, 2023

• Mitsubishi Tanabe’s Ueno Elected as New JPMA President
  May 26, 2023

• Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
  May 24, 2023

• Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
  May 19, 2023

• Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
  May 15, 2023

• Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
  May 10, 2023

• JPMA Nudges Govt to Take Special Measures for Infectious Disease Biz
  May 9, 2023

• JPWA Urges Govt to Take Steps against Drug Shortages Based on Overseas Examples
  May 9, 2023

• Trade Group Demands Better Market Environment for Regenerative Medicine, Proposes New Pricing Model
  April 28, 2023

• Health Care Science Institute Proposes Policies for Solving Distribution Issues, Reviewing Pricing System
  April 26, 2023

• Just Protecting Prices of On-Patent Meds Would Lead to 1.3% Growth in Japan: PhRMA
  April 24, 2023

• Asian Pharma Groups Adopt Position Paper to Push E-Labeling
  April 20, 2023

• Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
  April 17, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• …
• Next ›
• 最終 »